CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing is a research paper published in Proceedings of the National Academy of Sciences (2023). On theSindex it has a DataRank of 0. It has been cited 100 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH/NCI
Grant: CA229812
NIH/NCI
Grant: CA240004
NIH/NCI
Grant: CA259599
NIH/NCI
Grant: CA226981
Department of Defense
Grant: W81XWH2110433
NCI NIH HHS
Grant: R01 CA175033
NCI NIH HHS
Grant: R01 CA226981
NCI NIH HHS
Grant: R01 CA240004
NCI NIH HHS
Grant: R01 CA229812
NCI NIH HHS
Grant: P30 CA016059
NCI NIH HHS
Grant: R01 CA259599
National Institutes of Health
Grant: 5R01CA226981-04
Prevention of post-therapy breast cancer metastasis
National Institutes of Health
Grant: 5R01CA229812-03
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
National Institutes of Health
Grant: 4P30CA016059-35
Massey Cancer Center Support Grant
National Institutes of Health
Grant: 1R01CA259599-01
Interplay between tumor and microenvironment in bone metastasis
National Institutes of Health
Grant: 5R01CA240004-02
A novel role of IGFBP7 in the microenvironment of hepatocellular carcinoma
FWCI
9.58
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
Additional file 1 of KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination